Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis
More than 75% of cost utility analyses were published one year or more after publication of the trial's clinical results Comment We found a substantial delay in the publication of cost utility analyses, suggesting that reliable economic data are usually not available, at least in peer reviewed...
Saved in:
Published in | BMJ Vol. 328; no. 7455; pp. 1536 - 1537 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
British Medical Journal Publishing Group
26.06.2004
BMJ Publishing Group British Medical Association BMJ Publishing Group LTD BMJ Publishing Group Ltd |
Edition | International edition |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | More than 75% of cost utility analyses were published one year or more after publication of the trial's clinical results Comment We found a substantial delay in the publication of cost utility analyses, suggesting that reliable economic data are usually not available, at least in peer reviewed journals, for decision makers when decisions on adoption and reimbursement are typically made. [...]compared with trial results, dissemination of cost utility analyses takes place in journals with lower readership and influence. |
---|---|
Bibliography: | href:bmj-328-1536.pdf Correspondence to: D Greenberg, Harvard Clinical Research Institute, 930 Commonwealth Avenue, Boston, MA 02215, USA local:bmj;328/7455/1536 ArticleID:bmj.38079.502326.AE PMID:15100148 istex:C3B6CF3A8A1952C20C5D64162B89FCC7369B97B7 ark:/67375/NVC-BQ2Q07ZX-9 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 This article was posted on bmj.com on 20 April 2004: http://bmj.com/cgi/doi/10.1136/bmj.38079.502326.AE Contributors: DG had the original idea for the study, drafted the first version of the manuscript, did the statistical analysis, and is the guarantor. All authors extracted data, interpreted the findings, critically revised the report, and approved the final version. Funding: Supported by grant number R01 HS10919 from the Agency for Health Care Research and Quality. Correspondence to: D Greenberg, Harvard Clinical Research Institute, 930 Commonwealth Avenue, Boston, MA 02215, USA dan.greenberg@hcri.harvard.edu We thank Richard H Chapman for his contribution to the design and analysis of the Harvard School of Public Health Cost-Effectiveness Analysis Registry. Competing interests: None declared. |
ISSN: | 0959-8138 0959-8146 1468-5833 1756-1833 |
DOI: | 10.1136/bmj.38079.502326.AE |